Aura Biosciences (AURA) Total Current Liabilities (2020 - 2026)
Aura Biosciences' (AURA) quarterly Total Current Liabilities came in at $16.7 million in Q1 2026, up 37.35% YoY from $12.2 million in Q1 2025, and down 9.12% on a QoQ basis from $18.4 million in Q4 2025.
Aura Biosciences (AURA) Total Current Liabilities (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Total Current Liabilities data on file, last reported at $16.7 million in Q1 2026.
- Quarterly Total Current Liabilities rose 37.35% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (up 37.35% YoY) and the FY2025 annual result came in at $18.4 million, up 23.27% from the prior year.
- Total Current Liabilities fell to $16.7 million in Q1 2026, from $18.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $18.8 million in Q3 2025 to a low of $5.0 million in Q1 2022.
- A 5-year average of $11.9 million and a median of $10.9 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 70.88% — and 2023, when it rose 9.33%.
- Tracing AURA's Total Current Liabilities over 5 years: stood at $10.5 million in 2022, then rose by 18.17% to $12.4 million in 2023, then gained by 20.68% to $14.9 million in 2024, then climbed by 23.27% to $18.4 million in 2025, then declined by 9.12% to $16.7 million in 2026.
- The last three Total Current Liabilities figures came in at $16.7 million (Q1 2026), $18.4 million (Q4 2025), and $18.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 19.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.56 Mn |
| Mar 31, 2026 | 16.71 Mn |
| Dec 31, 2025 | 18.38 Mn |
| Sep 30, 2025 | 18.82 Mn |
| Jun 30, 2025 | 14.85 Mn |
| Mar 31, 2025 | 12.16 Mn |
| Dec 31, 2024 | 14.91 Mn |
| Sep 30, 2024 | 14.71 Mn |
| Jun 30, 2024 | 10.55 Mn |
| Mar 31, 2024 | 9.66 Mn |
| Dec 31, 2023 | 12.36 Mn |
| Sep 30, 2023 | 10.89 Mn |
| Jun 30, 2023 | 8.90 Mn |
| Mar 31, 2023 | 8.11 Mn |
| Dec 31, 2022 | 10.46 Mn |
| Sep 30, 2022 | 9.96 Mn |
| Jun 30, 2022 | 5.81 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 7.36 Mn |
| Sep 30, 2021 | 5.83 Mn |